PLOS ONE: Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis
First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study | Scientific Reports
Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma - Gleeson - 2020 - Cancer Medicine - Wiley Online Library
Overall survival and time to treatment failure for patients eligible... | Download Scientific Diagram
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
Adding bevacizumab improves overall survival in NSCLC
Overall survival for patients randomized to receive (A) bevacizumab (n... | Download Scientific Diagram
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
Bevacizumab and chemotherapy for recurrent glioblastoma | Neurology
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial - The Lancet Respiratory
a: Overall survival in treatment groups with bevacizumab alone or... | Download Scientific Diagram
Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer - European Journal of Cancer
Avastin® (bevacizumab) Clinical Trials | MRCC Treatment
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM
Survival and Bevacizumab in Early Breast Cancer: Time to Reconsider? - The ASCO Post
Updated Results From IMbrave150 Underscore the Benefit of Frontline Atezolizumab Plus Bevacizumab in Unresectable HCC
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study - Gynecologic Oncology
PLOS ONE: Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study
Valganciclovir and bevacizumab for recurrent glioblastoma: A single-institution experience
Bevacizumab Progression-free Survival Benefit Upheld in AVEREL Trial - The ASCO Post
Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer - Gynecologic Oncology
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer | NEJM
TURANDOT: First-Line Bevacizumab Plus Capecitabine Shows Non-Inferior Overall Survival versus Bevacizumab plus Paclitaxel for Metastatic Breast Cancer | ESMO
Avastin® (bevacizumab) Clinical Trials | MCRC Treatment
